DnB Asset Management
ADMA icon

DnB Asset Management’s ADMA Biologics ADMA Stock Holding History

DnB Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Buy
+15,268
New +$241K ﹤0.01% 1204

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

DnB Asset Management's ADMA Position: Q1 2026 in Review

DnB Asset Management opened a new position in ADMA Biologics (ADMA) in Q1 2026: 15,268 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #1204 among its holdings.

356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • DnB Asset Management held 15,268 shares of ADMA Biologics worth $138K as of Q1 2026.
  • ADMA Biologics was a new DnB Asset Management position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of DnB Asset Management's portfolio in Q1 2026, its #1204 holding.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.